Severe bronchial asthma patient care organization in various regions of the Russian Federation. From endotypes and phenotypes of bronchial asthma to personalized choice of therapy
- 作者: Avdeev S.1, Volkova O.2, Demko I.3, Ignatova G.4, Leshchenko I.5, Kanukova N.6, Kudelya L.7, Nevzorova V.8, Nedashkovskaya N.9, Ukhanova O.10, Shulzhenko L.11, Fassakhov R.12
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- City Clinical Hospital No.6
- Voyno-Yasenetsky Krasnoyarsk State Medical University
- South Ural State Medical University
- Ural State Medical University
- Stavropol Regional Clinical Consultative and Diagnostic Center
- Novosibirsk State Medical University
- Pacific State Medical University
- Regional Clinical Hospital No.2
- Stavropol State Medical University
- Kuban State Medical University
- Kazan (Volga) Federal University
- 期: 卷 92, 编号 2 (2020)
- 页面: 119-123
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/33924
- DOI: https://doi.org/10.26442/00403660.2020.02.000555
- ID: 33924
如何引用文章
全文:
详细
The meeting of the Expert board was held in Moscow on June 24, 2019, at which the following issues were considered: the applicability of a new terminology characterizing asthma endotypes and phenotypes in real clinical practice, the effect of phenotypes and biomarkers in patients with bronchial asthma on the choice of biological drug, as well as the optimal clinical profiles of patients for whom dupilumab is most effective, taking into account the data of the III phase clinical trials, regional features of medical care and changes in updated international clinical guidelines for the diagnosis and treatment of asthma. The Expert board included members of leading Russian scientific and educational medical institutions: S.N. Avdeev, corresponding member of the Russian Academy of Sciences, prof., MD; O.A. Volkova, Ph.D.; I.V. Demko, prof., MD; G.L. Ignatova, prof., MD; I.V. Leshchenko, prof., MD; Kanukova N.A.; Kudelya L.M., prof., MD; V.A. Nevzorova, prof., MD; N.G. Nedashkovskaya; O.P. Ukhanova, prof., MD; L.V. Shulzhenko, prof., MD; R.S. Fassakhov, prof., MD.
作者简介
S. Avdeev
Sechenov First Moscow State Medical University (Sechenov University)
编辑信件的主要联系方式.
Email: serg_avdeev@list.ru
член-корр. РАН, проф., д.м.н., зав. каф. пульмонологии
俄罗斯联邦, MoscowO. Volkova
City Clinical Hospital No.6
Email: serg_avdeev@list.ru
к.м.н., зам. главного врача по стационарной медицинской помощи Больничного комплекса №1 Городской клинической больницы №6
俄罗斯联邦, IzhevskI. Demko
Voyno-Yasenetsky Krasnoyarsk State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0001-8982-5292
д.м.н., проф., зав. каф. внутренних болезней №2 с курсом ПО
俄罗斯联邦, KrasnoyarskG. Ignatova
South Ural State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-0877-6554
д.м.н., проф., зав. каф. терапии института дополнительного профессионального образования
俄罗斯联邦, ChelyabinskI. Leshchenko
Ural State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-1620-7159
д.м.н., заслуженный врач РФ, проф. каф. фтизиатрии и пульмонологии; научный руководитель клиники МО «Новая больница»
俄罗斯联邦, YekaterinburgN. Kanukova
Stavropol Regional Clinical Consultative and Diagnostic Center
Email: serg_avdeev@list.ru
зав. отд-нием пульмонологии
俄罗斯联邦, StavropolL. Kudelya
Novosibirsk State Medical University
Email: serg_avdeev@list.ru
д.м.н., проф. каф. внутренних болезней; зав. пульмонологическим отд-нием
俄罗斯联邦, NovosibirskV. Nevzorova
Pacific State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-0117-0349
д.м.н., проф., директор института терапии и инструментальной диагностики
俄罗斯联邦, VladivostokN. Nedashkovskaya
Regional Clinical Hospital No.2
Email: serg_avdeev@list.ru
зав. отд-нием пульмонологии
俄罗斯联邦, Rostov-on-DonO. Ukhanova
Stavropol State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-7247-0621
д.м.н., проф. каф. иммунологии
L. Shulzhenko
Kuban State Medical University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-2110-0970
д.м.н., проф., главный внештатный терапевт, проф. каф. пульмонологии, руководитель отд-ния пульмонологии ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница №1 им. проф. С.В. Очаповского»
俄罗斯联邦, KrasnodarR. Fassakhov
Kazan (Volga) Federal University
Email: serg_avdeev@list.ru
ORCID iD: 0000-0001-9322-2689
д.м.н., проф. каф. фундаментальных основ клинической медицины института фундаментальной медицины и биологии
俄罗斯联邦, Kazan参考
- GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X
- Chuchalin A, Khaltaev N, Antonov N, Galkin D. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Inter J Chronic Obstructive Pulmonary Disease. 2014:963. doi: 10.2147/copd.s67283
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2018 update). Accessed June 25, 2019. Available at: www.ginasthma.org
- Chung KF, Wenzel SE, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respiratory J. 2013;43(2):343-73. doi: 10.1183/09031936.00202013
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nature Medicine. 2012;18(5):716-25. doi: 10.1038/ nm.2678
- Robinson D, Humbert M, Buhl R, et al. Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exper Allergy. 2017;47(2):161-75. doi: 10. 1111/cea.12880
- Fahy JV. Type-2 inflammation in asthma — present in most, absent in many. Nature Reviews Immunol. 2014;15(1):57-65. doi: 10.1038/ nri3786
- Gauthier M, Ray A, Wenzel SE. Evolving Concepts of Asthma. Amer J Respir Criti Care Med. 2015;192(6):660-8. doi: 10.1164/rccm.201504-0763pp
- Woodruf PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Amer J Respir Crit Care Med. 2009;180(5):388-95. doi: 10.1164/rccm.200903-0392oc
- Dunican EM, Fahy JV. The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations. Ann Amer Thorac Soc. 2015;12(Suppl. 2):S144-S149. doi: 10.1513/AnnalsATS.201506-377AW
- Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-94. doi: 10.1016/j.jaci.2013.07.036
- Международная классификация болезней 10-го пересмотра. Ссылка активна на 19.07.2019 [10th International Classification of Diseases. Accessed July 19, 2019 (In Russ.)]. Available at: https://mkb-10.com/index.php?pid=9170
- GINA Pocket Guide, “Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. V2.0, April 2019”. Accessed July 19, 2019. Available at: https://ginasthma.org/ severeasthma/
- Инструкция по медицинскому применению лекарственного препарата Нукала. Ссылка активна на 19.07.2019 [Instructions for the medical use of the drug Nukala. Accessed July 19, 2019 (In Russ.)]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c9500b78-9cf6-45c9-8336-16ef5348b722&t=
- Инструкция по медицинскому применению лекарственного препарата Синкейро. Ссылка активна на 19.07.2019 [Instructions for the medical use of the drug Sinkeiro. Accessed July 19, 2019 (In Russ.)]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=d2f201db-73ab-465c-afb8-3a04f78e1608&t=
- Инструкция по медицинскому применению лекарственного препарата Фазенра. Ссылка активна на 19.07.2019 [Instructions for the medical use of the drug Fazenra. Accessed July 19, 2019 (In Russ.)]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=92c7fd3d-70ee-4463-add3 e36de75ddd13&t=.
- Инструкция по медицинскому применению лекарственного препарата Дупиксент® (дупилумаб). Регистрационный номер ЛП-005440 от 04.04.2019. Ссылка активна на 19.07.2019 [Instructions for the medical use of the drug Dupiksent® (dupilumab). Registratsionnyi nomer LP-005440 ot 04.04.2019. Accessed July 19, 2019 (In Russ.)]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=02f74b3c-76a5-4459-bcbb-e4c22516e145&t=
- Castro M, Corren J, Pavord ID, Maspero J, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. New Engl J Med. 2018;378(26):2486-96. doi: 10.1056/nejmoa1804092
- Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. New Engl J Med. 2018;378(26):2475-85. doi: 10.1056/nejmoa1804093
- Bachert C, Han JK, Desrosiers M, Hellings PW, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-50. doi: 10.1016/s0140-6736(19)31881-1